Acquisitions12 Oct 2026, 03:18 pm
Tavexia Lifecare Rebrands, Acquires 60% Stake in Meyonex for ₹67.19 Cr
AI Summary
Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, has announced a rebranding and strategic expansion into high-growth verticals including APIs, finished formulations, CDMO/CRAMS, and nutraceuticals. The company has also acquired a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore (2,09,97,180 shares at ₹32 per share). This acquisition provides immediate operational capabilities and significant synergies. Tavexia plans strategic fund-raising to support its growth roadmap in the resilient pharmaceutical and lifecare sector, leveraging global supply-chain diversification and increasing demand for specialized services.
Key Highlights
- Rebranded to Tavexia Lifecare, expanding into APIs, formulations, CDMO, and nutraceuticals.
- Acquired 60% stake in Meyonex Pharmaceuticals for ₹67.19 Crore.
- Acquisition brings established manufacturing and commercial operations.
- Plans strategic fund-raising to finance future growth initiatives.
- Positioned to capitalize on sector tailwinds in pharma and lifecare.
Price Impact
More from SATTVASUKU